A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata

NCT02684097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Alopecia Areata

Interventions

DRUG: Tralokinumab
DRUG: Placebo

Sponsor

Emma Guttman